Uterine Fibroids Market Report and Forecast 2025-2034

The uterine fibroids market was valued at USD 13.41 Billion in 2024, driven by advancements in treatment options across the 8 major markets. The market is expected to grow at a CAGR of 7.30% during the forecast period of 2025-2034, with the values likely to reach USD 27.13 Billion by 2034.

Uterine Fibroids Market Overview

Uterine fibroids, which are non-cancerous growths located in the uterus, are frequently seen in women of African descent. Possible symptoms are menstrual bleeding, pelvic pain, frequent urination, bloating, and reproductive problems. Diagnosis is conducted through pelvic exams, imaging procedures, and blood tests, and treatment is tailored according to the symptoms. Increased demand for fertility-preserving treatments and the development of symptomatic treatments are expected to drive the market growth in the forecast period.

Uterine Fibroids Market Growth Drivers

Technological Advancement and Innovation in Treatment Options to Drive Market Growth

Advancements in technology and innovation in treatment options are causing a rise in demand in the market for uterine fibroids. UConn Health, a hospital in the United States, has implemented the Sonata® treatment, demonstrating a revolutionary option to standard surgeries and providing patients with a less invasive choice that allows for quicker recovery and better results. Thus, the advancement in medical technology is one of the primary drivers of the market.

Uterine Fibroids Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Development of Symptomatic Treatments

The current market trend is towards developing symptomatic treatments, with hysterectomy being the main option, but there is a growing focus on non-invasive alternatives that preserve the uterus and fertility, such as uterine-sparing procedures and medical therapies.

Health Literacy to Affect the Market Landscape Significantly

Health literacy is a significant trend in the uterine fibroid treatment landscape in the United States. It impacts decisions on treatment and highlights the importance of healthcare professionals prioritizing patient education to enhance comprehension of conditions and treatment alternatives.

Increased Demand for Fertility-Preserving Treatments

The increasing need for fertility-preserving treatments is set to fuel market expansion. Medical therapies are being emphasized as the primary approach for managing uterine fibroids, aiming to avoid surgery while preserving fertility for women of reproductive age.

Growing Demand for Non-Surgical and Minimally Invasive Treatments

The market is witnessing a trend toward the growing demand for non-surgical options to treat fibroids driven by varying symptom severity. Patients can manage milder symptoms with medication or lifestyle changes, aligning with rising interest in non-invasive treatments.

Uterine Fibroids Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class:

• Progestin-Releasing Intrauterine Device (IUD)& Contraceptives
• Gonadotropin-Releasing Hormone (GnRH) Antagonists
• Gonadotropin-Releasing Hormone (GnRH) Agonists
• Non-Hormonal Medications
• Others

Market Breakup by Type:

• Subserosal Fibroids
• Intramural Fibroids
• Submucosal Fibroids
• Pedunculated Fibroids
• Others

Market Breakup by End User:

• Hospitals
• Clinics
• Diagnostic Centers
• Research Laboratories
• Others

Market Breakup by Region:

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Uterine Fibroids Market Share

Market Segmentation Based on the Type to Witness Growth

The uterine fibroid market segmentation, based on type, includes subserosal fibroids, intramural fibroids, submucosal fibroids, and pedunculated fibroids, among others. Submucosal fibroids are expected to dominate the market, with emerging economies experiencing category expansion due to their development in the muscle layer of the uterus. Intramural fibroids are also increasing, impacting fertility rates, and requiring treatment.

Uterine Fibroids Market Analysis by Region

Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. The United States is expected to dominate the market share owing to the rising prevalence of uterine fibroids, increasing pregnancy complications due to fibroids, and the approval of novel treatment options.

Leading Players in the Uterine Fibroids Market

The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding, and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Pfizer Inc

Pfizer Inc. is a United States-based pharmaceutical company specializing in biopharmaceuticals for cardiovascular, metabolic, and women's health. In January 2024, Pfizer Canada collaborated with Sumitomo Pharma Canada to offer MYFEMBREE® for endometriosis and uterine fibroids in Canada.

AbbVie Inc

AbbVie Inc. based in North Chicago, Illinois, is a pharmaceutical company specializing in the development and commercialization of drugs for chronic and complex diseases. Their focus includes treatments for metabolic, rheumatological, neurological, and skin diseases, as well as hormonal and women's health conditions like hypothyroidism and uterine fibroids.

ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company focusing on developing novel therapies for women's reproductive health and pregnancy. In February 2022, they entered a licensing agreement with Theramex to commercialize Linzagolix, an oral GnRH antagonist for treating uterine fibroids and potentially endometriosis-associated pain.

Bayer AG

Bayer AG is a German pharmaceutical and biotechnology company that focuses on innovative solutions for disease prevention and treatment. They are a key player in the uterine fibroid market, with research efforts on drugs like Vilaprisan for treating symptomatic uterine fibroids.

Other players in the market include AstraZeneca.

Key Questions Answered in the Uterine Fibroids Market Report

• What was the uterine fibroids market value in 2024?
• What is the uterine fibroids market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is the market segmentation based on type?
• What is the market segmentation based on the drug class?
• What is the market breakup based on the end user?
• What are the major factors aiding the uterine fibroids market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the major drivers, opportunities, and restraints in the market?
• What are the major trends influencing the market?
• Which regional market is expected to dominate the market share in the forecast period?
• Which country is likely to experience elevated growth during the forecast period?
• Who are the key players involved in the uterine fibroids market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.